Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


β-Blockers rescue cardiomyocyte division defects

A reduction in cardiomyocyte numbers owing to decreased cell division might contribute to the cardiac complications seen in adult patients with tetralogy of Fallot, according to a new study. Analysis of heart tissue from infants with tetralogy of Fallot with pulmonary stenosis showed a higher percentage of binucleated cardiomyocytes, a trait linked to cytokinesis failure, than in normal hearts. Assays in mouse models revealed that cytokinesis failure in cardiomyocytes was associated with low expression of Ect2, mediated by β-adrenergic receptor (β-AR) signalling. Deficiency of β-ARs in neonatal mice or treatment with the β-blocker propranolol during the neonatal phase increased Ect2 expression and decreased cardiomyocyte binucleation, and led to increased cardiomyocyte numbers, improved cardiac function and attenuated remodelling after myocardial infarction in the adult. These findings suggest that treatment with β-blockers early after birth might rescue cytokinesis defects and prevent heart dysfunction in adulthood.


Original article

  1. Liu, H. et al. Control of cytokinesis by β-adrenergic receptors indicates an approach for regulating cardiomyocyte endowment. Sci. Transl Med. 11, eaaw6419 (2019)

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Irene Fernández-Ruiz.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fernández-Ruiz, I. β-Blockers rescue cardiomyocyte division defects. Nat Rev Cardiol 17, 6 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing